ddrg/super_eurlex huggingface dataset:
Non-opposition to a notified concentration

(Case M.9481 — CCS/DSG/CES)

(Text with EEA relevance)

(2019/C 379/02)

On 28 October 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in German and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9481. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Prior notification of a concentration

(Case M.9461 — AbbVie/Allergan)

(Text with EEA relevance)

(2019/C 392/11)

1. On 12 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — AbbVie Inc., (‘AbbVie’, United States), — Allergan plc (‘Allergan’, Ireland). AbbVie acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Allergan. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — AbbVie is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in the United States. AbbVie is engaged in the development and commercialisation of innovative medicines in six main therapeutic areas: immunology (including autoimmune diseases), oncology, virology, neuroscience/central nervous system disorders, metabolic diseases and pain associated with endometriosis; — Allergan is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in Ireland. Allergan is engaged in the development and commercialisation of medicines in four key therapeutic areas: medical aesthetics, eye care, neuroscience/central nervous system disorders and gastroenterology.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.9461 — AbbVie/Allergan Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).
Non-opposition to a notified concentration

(Case M.9520 — CVC/Robert Bosch Packaging Technology)

(Text with EEA relevance)

(2019/C 387/02)

On 7 November 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9520. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Prior notification of a concentration

(Case M.9583 — TPG/Hong Leong Group/Columbia Asia Healthcare)

Candidate case for simplified procedure

(Text with EEA relevance)

(2019/C 400/14)

1. On 18 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — TPG Asia VI SF Pte. Ltd. (‘TPG Asia’, Singapore), belonging to TPG Group, USA, — Hong Leong Healthcare Group Sdn Bhd (‘Hong Leong’, Malaysia), belonging to Hong Leong Group, Malaysia, — Columbia Asia Healthcare Pte. Ltd. (‘CAHSG’, Singapore). TPG Asia and Hong Leong acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of CAHSG. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — for TPG Asia: part of TPG Group, a private investment firm that manages a family of funds that invest in a variety of companies through acquisitions and corporate restructurings. TPG Asia forms part of the TPG Capital Asia platform, which focuses on Asian investments, — for Hong Leong: part of Hong Leong Group, a conglomerate with diversified businesses in banking and financial services, manufacturing and distribution, property development and investments, hospitality, and leisure. Hong Leong was established on August 20, 2019 for the purpose of acquiring CAHSG and will focus on the healthcare sector, — for CAHSG: the holding entity for the Columbia Asia Group, a private healthcare company founded in 1996 to provide accessible, affordable, and high-quality healthcare to meet the needs of the Asian population. CAHSG has 18 facilities across Asia: 12 hospitals in Malaysia, 2 hospitals and 1 clinic in Vietnam, and 3 hospitals in Indonesia. It currently also operates 11 hospitals in India, which will be carved out from the transaction perimeter.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.9583 — TPG/Hong Leong Group/Columbia Asia Healthcare Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.9579 — ENI/HitecVision/Norwegian Upstream Assets of ExxonMobil)

(Text with EEA relevance)

(2019/C 395/01)

On 18 November 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9579. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.9643 — ENGIE/Versicherungskammer/Portfolio Companies)

Candidate case for simplified procedure

(Text with EEA relevance)

(2019/C 405/11)

1. On 20 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings:

— ENGIE S.A. (France),

— Versicherungskammer Bayern Versicherungsanstalt des öffentlichen Rechts (Germany),

— SUN PV HOLDING which owns SolaireDigne, SolaireSignes, SolaireIstres 2, SAS du Soleil, SAS des Landes de la Motte, SolaireChatellerault and SolaireLaMotte (‘the Portfolio Companies’, all in France). These companies are currently wholly-owned by ENGIE S.A.

ENGIE S.A. (‘ENGIE’) and Versicherungskammer Bayern Versicherungsanstalt des öffentlichen Rechts (‘Versicherungskammer Bayern’) acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of SUN PV HOLDING (France).

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — for ENGIE: ENGIE is an industrial company active in the fields of gas and electricity supply as well as in energy services, — for Versicherungskammer Bayern: Versicherungskammer Bayern is a German public insurer which provides personal and property insurance, — for SUN PV HOLDING: SUN PV HOLDING will be active in the generation of electricity through a portfolio of photovoltaic power plants located in France.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9643 — ENGIE/Versicherungskammer/Portfolio Companies

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.9473 — Kirkbi/Blackstone/CPPIB/Merlin)

(Text with EEA relevance)

(2019/C 402/03)

On 18 October 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9473. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Prior notification of a concentration

(Case M.9694 — Hermes/Iridium/JV)

Candidate case for simplified procedure

(Text with EEA relevance)

(2019/C 414/09)

1. On 29 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Hermes GPE LLP (‘Hermes’, United Kingdom), — Iridium Conceciones de Infrastructuras S.A. (‘Iridium’, Spain), belonging to the ACS Group (‘ACS’, Spain), — JV (Spain), including: — Eix Diagonal Concessionària de la Generalitat de Catalunya (‘Eix Diagonal’, Spain), — Autovía del Pirineo S.A. (‘A-21’, Spain), — Autovía de los Pinares, S.A. (‘Aupisa’, Spain), — Concesionaria Santiago-Brión S.A. (‘Santiago-Brión’, Spain), — Reus-Alcover Concesionària de la Generalitat de Catalunya S.A. (‘Reus-Alcover’, Spain), — Autovía de la Mancha S.A. (‘Aumancha’, Spain), — Inversora de la Autovía de la Mancha S.A. (‘Inversora’, Spain). Hermes and Iridium acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of the whole of the JV, which will be managing the toll motorway concessions (i.e. Eix-Diagonal, A-21, Aupisa, Santiago-Brión, Reus-Alcover, Aumancha and Inversora, together the ‘Toll Motorway Concessions’). The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — for Hermes: is a leading specialist investor in global private markets specialising in developing bespoke and diversified private equity and infrastructure portfolios on behalf of its clients, — for Iridium: part of the Spanish construction group ACS, is active in the development, management and maintenance of concessions, — for the JV: active in the management of concessions in the transport sector, and will be managing the Toll Motorway Concessions.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.9694 — Hermes/Iridium/JV Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Prior notification of a concentration

(Case M.9645 — Platinum Equity Group/Cision)

Candidate case for simplified procedure

(Text with EEA relevance)

(2019/C 409/10)

1. On 28 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — Platinum Equity LLC (Platinum Equity Group, United States), — Cision Ltd (Cision, United States). Platinum Equity Group acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Cision. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are: — for Platinum Equity Group: group of entities controlled by Platinum Equity LLC specialised in the merger, acquisition and operation of companies that provide services and solutions to customers in a broad range of businesses, including information technology, telecommunications, logistics, metal services, manufacturing and distribution, at global level. — for Cision: supplier of public relations workflow software, media distribution, media intelligence and related products and services to public relations and marketing communications professionals, at global level.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M9645 — Platinum Equity Group/Cision Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Non-opposition to a notified concentration

(Case M.9620 — Bridgepoint/Vermaat)

(Text with EEA relevance)

(2019/C 424/02)

On 9 December 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9620. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.
Official Journal of the European Union

Prior notification of a concentration

(Case M.9636 — American Securities/Lindsay Goldberg/AECOM Management Services)

Candidate case for simplified procedure

(Text with EEA relevance)

(2019/C 420/11)

1. On 5 December 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) This notification concerns the following undertakings: — American Securities LLC (‘American Securities’, USA), — Goldberg Lindsay & Co. LLC (‘Lindsay Goldberg’, USA), — AECOM E&C Holdings, Inc., Maverick Newco LLC and AECOM International Holdings (UK) Limited (together ‘AECOM Management Services’, USA). American Securities and Lindsay Goldberg acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of AECOM Management Services. The concentration is accomplished by way of purchase of shares and assets.

2. The business activities of the undertakings concerned are: — for American Securities: private equity firm active in various industry sectors, including business services, consumer, healthcare, industrial and technology, — for Lindsay Goldberg: investment advisor to private equity funds in various industry sectors, — for AECOM Management Services: global provider of professional services to governments and related entities active in the defence sector.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified: M.9636 — American Securities/Lindsay Goldberg/AECOM Management Services Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: E-mail: COMP-MERGER-REGISTRY@ec.europa.eu Fax +32 22964301 Postal address: European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2) OJ C 366, 14.12.2013, p. 5.
Official Journal of the European Union

Withdrawal of notification of a concentration

(Case M.9607 — ENGIE/Omnes Capital/Predica/EGI9 Portfolio)

(Text with EEA relevance)

(2019/C 434/03)

Council Regulation (EC) No 139/2004

On 22 November 2019, the European Commission received notification (1) of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (‘Merger Regulation’).

On 18 December 2019, the notifying parties informed the Commission that they withdrew their notification.

(1) OJ C 405, 2.12.2019, p. 12.
Non-opposition to a notified concentration

(Case M.9598 — Allianz/T&R)

(Text with EEA relevance)

(2019/C 428/01)

On 5 December 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9598. EUR-Lex is the online access to European law.

(1) OJ L 24, 29.1.2004, p. 1.